secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001493152-24-052029
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus assigns exclusive ophthalmic license to majority-owned subsidiary VisiRose
--------------------------------------------------------------------------------

- Assigns exclusive license with University of Miami for photodynamic antimicrobial therapy in ophthalmology to VisiRose, effective Dec 9, 2024.
- VisiRose is a majority-owned subsidiary focused on developing rose bengal sodium for ophthalmology diseases and disorders.
- University of Miami approved assignment and novation, releasing Provectus from future obligations under the license.
- Provectus grants VisiRose a non-exclusive, worldwide, royalty-free license to Licensee Background IP as needed.
- Agreement reflects Provectus's strategy to separate ophthalmic assets into a dedicated subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224052029/0001493152-24-052029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224052029/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-052029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer